Enhertu

News

New data could move Enhertu into early breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.

News

Woman with breast cancer covering her chest with her hands

Enhertu poised to move first line in HER2+ breast cancer

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

News

AZ grabs pair of EU approvals for top cancer drugs

AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.

News

Enhertu extends survival in advanced gastric cancer

Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.

News

Enhertu gets first okay for HER2-ultralow breast cancer

Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

News

Dr Sam Roberts, NICE chief executive, said AstraZeneca and Daiichi Sankyo had not offered a fair price

NICE blames companies for breakdown in Enhertu talks

Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been abandoned, according to cost-effectiveness assessor NICE.

New data could move Enhertu into early breast cancer

Enhertu poised to move first line in HER2+ breast cancer

AZ grabs pair of EU approvals for top cancer drugs

Enhertu extends survival in advanced gastric cancer

Enhertu gets first okay for HER2-ultralow breast cancer

NICE blames companies for breakdown in Enhertu talks

23andMe study explains variable results with obesity drugs

Using AI-driven synthetic personas to take your insights fur...

Enhertu

Editor's Picks